BRIGHT MINDS BIOSCIENCES INC.
DRUG evidence brief
What we can confirm
- Market Cap:
- $640.8M
What it means
What to watch
Prepared research question
What matters most for DRUG—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DRUG
Bright Minds Biosciences Inc. is a clinical-stage biotechnology company developing highly selective 5-HT2 agonists for drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders.
Key risk: Clinical-stage revenue gap
Market Cap
$640.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 2 clinical trials for BRIGHT MINDS BIOSCIENCES INC..
Bright Minds Biosciences Inc. is a clinical-stage biotechnology company developing highly selective 5-HT2 agonists for drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders.
- Bright Minds is a clinical-stage biotech focused on highly selective 5-HT2 agonists for CNS disorders [news · published 2026-09-30].
- Lead candidate BMB-101 showed a 73.1% median reduction in absence seizures ≥3s (p=0.012) and a 63.3% median reduction in major motor seizures in DEE in a Phase 2 trial [news · published 2026-01-06].
- The company has initiated preparations for global registration following positive Phase 2 results [news · published 2026-01-06].
- A Phase 2 study for BMB-101 in Prader-Willi Syndrome (NOVA Study) was initiated in late 2025 [news · published 2025-11-06].
- Bright Minds is listed on the CSE (DRUG) and NASDAQ (DRUG) [news · published 2026-09-30].
What works
- Positive Phase 2 topline results for BMB-101 in absence seizures and DEE, with statistically significant seizure reduction and favorable safety [news · published 2026-01-06].
- Company has initiated global registration preparations, suggesting confidence in the data package [news · published 2026-01-06].
- Expanding pipeline into Prader-Willi Syndrome with a dedicated Phase 2a study (NOVA Study) [news · published 2025-11-06].
- Strong pre-clinical and clinical rationale supports the potential of 5-HT2C agonists as a first on-target mechanism for PWS [news · published 2025-11-06].
What to weigh
- The company is still in clinical stage with no approved products, meaning revenue generation is uncertain [news · published 2026-09-30].
- Phase 2 data, while positive, is from an open-label study; a placebo-controlled Phase 2 for PWS is ongoing but results are not yet available [catalyst].
- The biotech sector faces high cash burn rates; no financial runway details are provided in the available chunks [news · published 2026-05-21].
- Competition in the CNS space is intense, and regulatory approval is not guaranteed [news · published 2026-03-25].
From the filings
Quoted directly from source documents.
BMB-101 Phase 2 efficacy in absence seizures
“Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012”
News · January 6, 2026
BMB-101 Phase 2 efficacy in DEE
“DEE: 63.3% median reduction in major motor seizures”
News · January 6, 2026
Company initiated global registration preparations
“Company has initiated preparations for global registration”
News · January 6, 2026
Phase 2a NOVA study for PWS initiated
“Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prader-Willi Syndrome”
News · November 6, 2025
Catalyst timeline
- 2024-12-05 · Phase 2 start for BMB-101 in absence epilepsy and DEE (open-label) — An open-label Phase 2 study to evaluate efficacy, safety and tolerability of BMB-101 in adults with classic absence epilepsy or DEE.
- 2026-01-01 · Phase 2 start for BMB-101 in Prader-Willi Syndrome (placebo-controlled) — A randomized, double-blind, placebo-controlled Phase 2 study to assess efficacy, safety and tolerability of BMB-101 oral solution for PWS.
Risks & what to watch (3)›
Key risks
- Clinical-stage revenue gap — No approved products; revenue generation is uncertain until regulatory approval [news · published 2026-09-30].
- Open-label Phase 2 data — Positive Phase 2 results are from an open-label study; placebo-controlled data for PWS is pending [catalyst].
- Cash runway unknown — No financial runway details provided in available chunks; cash burn risk is typical for clinical-stage biotechs [news · published 2026-05-21].
What to watch
- Topline results from the Phase 2a NOVA study for BMB-101 in Prader-Willi Syndrome [news · published 2025-11-06].
- Progress on global registration preparations for BMB-101 in epilepsy [news · published 2026-01-06].
- Upcoming presentations at conferences such as the Cantor Global Healthcare Conference 2026 [news · published 2026-09-04].
- Any updates on financing or partnerships that could extend cash runway [news · published 2026-05-21].
Sources: Catalysts · News · Generated October 2, 2026 · How we verify sources →
Run BRIGHT MINDS BIOSCIENCES INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BRIGHT MINDS BIOSCIENCES INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 9.3%
- Days to cover
- 4.8
- Shares short
- 703,646
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DRUG short interestFrequently asked questions
What is the AI investment thesis for BRIGHT MINDS BIOSCIENCES INC.?
Bright Minds Biosciences Inc. is a clinical-stage biotechnology company developing highly selective 5-HT2 agonists for drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders.
Who is the CEO of BRIGHT MINDS BIOSCIENCES INC.?
Mr. Ian McDonald is the chief executive officer of BRIGHT MINDS BIOSCIENCES INC. (DRUG).
Where is BRIGHT MINDS BIOSCIENCES INC. headquartered?
BRIGHT MINDS BIOSCIENCES INC. (DRUG) is headquartered in New York, NY, United States.
What therapeutic areas does BRIGHT MINDS BIOSCIENCES INC. focus on?
BRIGHT MINDS BIOSCIENCES INC. develops therapies across Rare Disease, Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.